SG11202111333UA - Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) - Google Patents
Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)Info
- Publication number
- SG11202111333UA SG11202111333UA SG11202111333UA SG11202111333UA SG11202111333UA SG 11202111333U A SG11202111333U A SG 11202111333UA SG 11202111333U A SG11202111333U A SG 11202111333UA SG 11202111333U A SG11202111333U A SG 11202111333UA SG 11202111333U A SG11202111333U A SG 11202111333UA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- hepatitis
- virus
- active against
- novel phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19172007 | 2019-04-30 | ||
| EP19172401 | 2019-05-02 | ||
| PCT/EP2020/061930 WO2020221816A1 (en) | 2019-04-30 | 2020-04-29 | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111333UA true SG11202111333UA (en) | 2021-11-29 |
Family
ID=70391140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111333UA SG11202111333UA (en) | 2019-04-30 | 2020-04-29 | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220227785A1 (en) |
| EP (1) | EP3962912A1 (en) |
| JP (1) | JP2022531199A (en) |
| KR (1) | KR20220002499A (en) |
| CN (1) | CN113767102A (en) |
| AU (1) | AU2020265390A1 (en) |
| BR (1) | BR112021021580A2 (en) |
| CA (1) | CA3138384A1 (en) |
| CL (1) | CL2021002794A1 (en) |
| CU (1) | CU20210089A7 (en) |
| EC (1) | ECSP21078893A (en) |
| IL (1) | IL287240A (en) |
| MX (1) | MX2021013086A (en) |
| SG (1) | SG11202111333UA (en) |
| TW (1) | TW202106685A (en) |
| UY (1) | UY38683A (en) |
| WO (1) | WO2020221816A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3080971A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| EP4229062A1 (en) | 2020-10-15 | 2023-08-23 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19817264A1 (en) | 1998-04-18 | 1999-10-21 | Bayer Ag | New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents |
| AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
| WO2001006840A1 (en) | 1999-04-23 | 2001-02-01 | Jonathan Dallas Toye | Sheet fastening and anchoring component |
| WO2001045712A1 (en) | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
| JP2008502741A (en) | 2004-06-09 | 2008-01-31 | メルク エンド カムパニー インコーポレーテッド | HIV integrase inhibitor |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| CN106166157B (en) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | As the sulfonamides heterocyclic carbamate derivatives for preventing hepatitis b virus infected antivirotic |
| EA026368B1 (en) | 2011-12-21 | 2017-03-31 | Новира Терапьютикс, Инк. | Hepatitis b antiviral agents |
| CA2858647C (en) | 2012-01-06 | 2020-03-31 | Janssen R&D Ireland | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b. |
| HUE031400T2 (en) | 2012-08-28 | 2017-07-28 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| SG10201709133QA (en) | 2012-08-28 | 2017-12-28 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| SI2997019T1 (en) | 2013-05-17 | 2018-12-31 | Janssen Sciences Ireland Uc, | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| TW201512193A (en) | 2013-05-17 | 2015-04-01 | Hoffmann La Roche | Novel 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| PL3024819T3 (en) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CN105828823B (en) | 2013-10-18 | 2019-06-14 | 美国印第安纳大学研究和技术公司 | Hepatitis type B virus assembles effector |
| US9115113B2 (en) | 2013-11-14 | 2015-08-25 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| SI3114128T1 (en) | 2014-03-07 | 2019-04-30 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| DK3116316T3 (en) | 2014-03-13 | 2019-08-19 | Univ Indiana Res & Tech Corp | ALLOSTERIC MODULATORS OF HEPATITIS B CORE PROTEIN |
| WO2015144093A1 (en) | 2014-03-28 | 2015-10-01 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| AU2015255656A1 (en) | 2014-05-09 | 2016-11-10 | Assembly Biosciences, Inc. | Methods and compositions for treating hepatitis B virus infections |
| RU2664329C1 (en) | 2014-08-14 | 2018-08-16 | Ф. Хоффманн-Ля Рош Аг | Novel piridazones and triazinones for treatment and preventing of hepatitis b virus infection |
| AU2015358561A1 (en) | 2014-12-02 | 2017-06-08 | Novira Therapeutics, Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for HBV treatment |
| US9518057B2 (en) | 2014-12-30 | 2016-12-13 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
| MA41338B1 (en) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Pyrazine compounds for the treatment of infectious diseases |
| SG10201912847QA (en) | 2015-03-16 | 2020-02-27 | Hoffmann La Roche | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| EP3283472B1 (en) | 2015-04-17 | 2021-04-14 | Indiana University Research & Technology Corporation | Hepatitis b viral assembly effectors |
| JP6462155B2 (en) | 2015-05-04 | 2019-01-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| EP3325477B1 (en) | 2015-07-21 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TW201720802A (en) | 2015-09-15 | 2017-06-16 | 艾森伯利生物科學公司 | Hepatitis B core protein modulators |
| AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| EP3372606B1 (en) | 2015-11-04 | 2020-04-08 | Qilu Pharmaceutical Co., Ltd | Crystal form, preparation method and intermediate of dihydropyrido ring compound |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102398439B1 (en) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | Hepatitis B antiviral drugs |
| JP6581745B2 (en) | 2016-04-06 | 2019-09-25 | シャンハイ ジモン バイオファーマ カンパニー リミテッドＳｈａｎｇｈａｉ Ｚｈｉｍｅｎｇ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | Pyrazole-oxazolidinone compound of anti-hepatitis B virus |
| CN109153682B (en) | 2016-05-20 | 2021-05-25 | 豪夫迈·罗氏有限公司 | Novel pyrazine compounds with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases |
| CA3029566A1 (en) * | 2016-06-29 | 2018-01-04 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis b infections |
| CA3029688A1 (en) * | 2016-06-29 | 2018-01-04 | Novira Therapeutics, Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011163A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| EP3484885B1 (en) | 2016-07-14 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JOP20190024A1 (en) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Substituted pyrrolizine compounds and uses thereof |
| WO2018052967A1 (en) | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| CA3055194A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| EP3601216B1 (en) | 2017-03-21 | 2023-10-25 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection |
| JP7123429B2 (en) | 2017-05-04 | 2022-08-23 | シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド | Bicyclic fused ring system nucleocapsid inhibitors and their use as drugs to treat hepatitis B |
| US11247998B2 (en) | 2017-07-27 | 2022-02-15 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| TW201912153A (en) | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | Compounds, compositions and methods for treating hepatitis b |
| US10759774B2 (en) | 2017-09-28 | 2020-09-01 | The Curators Of The University Of Missouri | Inhibitors of hepatitis B virus targeting capsid assembly |
| AR117188A1 (en) * | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV) |
-
2020
- 2020-04-29 KR KR1020217038548A patent/KR20220002499A/en unknown
- 2020-04-29 SG SG11202111333UA patent/SG11202111333UA/en unknown
- 2020-04-29 CN CN202080032421.6A patent/CN113767102A/en active Pending
- 2020-04-29 US US17/607,634 patent/US20220227785A1/en active Pending
- 2020-04-29 AU AU2020265390A patent/AU2020265390A1/en not_active Abandoned
- 2020-04-29 CA CA3138384A patent/CA3138384A1/en active Pending
- 2020-04-29 MX MX2021013086A patent/MX2021013086A/en unknown
- 2020-04-29 JP JP2021564362A patent/JP2022531199A/en active Pending
- 2020-04-29 CU CU2021000089A patent/CU20210089A7/en unknown
- 2020-04-29 BR BR112021021580A patent/BR112021021580A2/en not_active IP Right Cessation
- 2020-04-29 EP EP20720853.9A patent/EP3962912A1/en not_active Withdrawn
- 2020-04-29 WO PCT/EP2020/061930 patent/WO2020221816A1/en unknown
- 2020-04-30 TW TW109114652A patent/TW202106685A/en unknown
- 2020-05-04 UY UY0001038683A patent/UY38683A/en unknown
-
2021
- 2021-10-13 IL IL287240A patent/IL287240A/en unknown
- 2021-10-24 CL CL2021002794A patent/CL2021002794A1/en unknown
- 2021-10-25 EC ECSENADI202178893A patent/ECSP21078893A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220002499A (en) | 2022-01-06 |
| IL287240A (en) | 2021-12-01 |
| BR112021021580A2 (en) | 2022-01-04 |
| CL2021002794A1 (en) | 2022-06-17 |
| TW202106685A (en) | 2021-02-16 |
| ECSP21078893A (en) | 2021-11-30 |
| CU20210089A7 (en) | 2022-06-06 |
| US20220227785A1 (en) | 2022-07-21 |
| CA3138384A1 (en) | 2020-11-05 |
| CN113767102A (en) | 2021-12-07 |
| MX2021013086A (en) | 2021-11-17 |
| AU2020265390A1 (en) | 2021-12-23 |
| EP3962912A1 (en) | 2022-03-09 |
| WO2020221816A1 (en) | 2020-11-05 |
| JP2022531199A (en) | 2022-07-06 |
| UY38683A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202003746UA (en) | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| ZA202002249B (en) | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| IL287240A (en) | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) | |
| IL275427A (en) | Hepatitis b virus (hbv) vaccines and uses thereof | |
| IL282587A (en) | Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv) | |
| SI3898668T1 (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
| MX2021006997A (en) | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same. | |
| IL282598A (en) | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| IL282480A (en) | Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| HUE055343T2 (en) | Treatment of hepatitis delta virus infection with interferon lambda | |
| IL275429A (en) | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines | |
| IL275423A (en) | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) | |
| IL290924A (en) | Hepatitis b virus vaccines | |
| IL282648A (en) | Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv) | |
| WO2019222238A3 (en) | Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| ZA202104244B (en) | Recombinant viruses and the uses thereof | |
| IL277128A (en) | Hepatitis b vaccines and uses of the same | |
| IL282687A (en) | Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv) | |
| IL266526A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| IL287278A (en) | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| IL287227A (en) | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) | |
| IL287269A (en) | Novel oxalyl piperazines active against the hepatitis b virus (hbv) | |
| EP3784686C0 (en) | Rubella virus spike construct | |
| HK1259329A1 (en) | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus | |
| IL282696A (en) | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |